Status:

TERMINATED

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Lead Sponsor:

AbbVie

Conditions:

Exocrine Pancreatic Insufficiency (EPI)

Eligibility:

All Genders

21+ years

Phase:

PHASE4

Brief Summary

This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an addi...

Eligibility Criteria

Inclusion

  • Participant has diagnosed cancer of pancreas with biopsy and/or radiography, with a life expectancy of at least 5 months at screening
  • Participant's pancreatic cancer must involve the head and/or neck of the pancreas
  • Confirmed exocrine pancreatic insufficiency (EPI) as evidenced by fecal elastase-1 (FE-1) ≤ 150 µg/g stool at screening
  • A positive Sudan stain for participants without history of fat malabsorption (fat malabsorption is defined as clinical steatorrhea, or measured stool fat \> 7 g/day, or positive stool results by Sudan stain) within 1 week of screening -- Positive stool results are defined as increased level of neutral OR total fats

Exclusion

  • Participant has neuroendocrine pancreatic cancer
  • Participant has fibrosing colonopathy
  • Participant has any other malignancy within 1 year of screening
  • Participant has uncontrolled gout, including those with a recent flare within 60 days of screening
  • Participant has other significant organ or bone marrow abnormality within 60 days of screening

Key Trial Info

Start Date :

February 25 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 23 2022

Estimated Enrollment :

1 Patients enrolled

Trial Details

Trial ID

NCT03859869

Start Date

February 25 2020

End Date

March 23 2022

Last Update

June 5 2023

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Alabama Oncology /ID# 207770

Birmingham, Alabama, United States, 35223-2437

2

Banner University of Arizona Medical Center Phoenix /ID# 208402

Phoenix, Arizona, United States, 85006

3

UCSF Fresno /ID# 205757

Fresno, California, United States, 93701-2302

4

Stanford University School of Med /ID# 208821

Stanford, California, United States, 94305-2200

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) | DecenTrialz